Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: No adverse effect of low-dose fluconazole prophylaxis on incidence and outcome

Bone Marrow Transplantation

Volumn 28, Issue 9, 2001, Pages 873-878

  Safdar, A ^a   Van Rhee, F ^a   Henslee Downey, J P ^a   Singhal, S ^a   Mehta, J ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

BMT; C. glabrata; C. krusei; Fluconazole prophylaxis; Fungemia

Indexed keywords

FLUCONAZOLE;

ADULT; AGRANULOCYTOSIS; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTEREMIA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDIASIS; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNGEMIA; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC CYSTITIS; HUMAN; INCIDENCE; MALE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; RECIPIENT; SIDE EFFECT; SURVIVAL TIME; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; BACTEREMIA; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDIASIS; CHILD; COMORBIDITY; CROSS INFECTION; CYSTITIS; FEMALE; FLUCONAZOLE; FUNGEMIA; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; INCIDENCE; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; RISK; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0035201070     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703252     Document Type: Article

References (38)

1. Fungemia caused by 'nonpathogenic' yeasts
2. Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality
3. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
4. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System
5. Candida infections in bone marrow transplant recipients
6. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia
7. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team
8. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - A prospective, randomized, double-blind study
9. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: Long-term follow-up of a randomized, placebo-controlled trial
10. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
11. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
12. Retrospective analysis of yeast colonization and infections in paediatric bone marrow transplant recipients
13. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team
14. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation
15. Infections in patients with neoplastic diseases
16. Definitions of Candida infections
17. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
18. The epidemiology of hematogenous candidiasis caused by different Candida species
19. Candida krusei fungemia: An escalating serious infection in immunocompromised patients
20. Use of partially mismatched related donors extends access to allogeneic marrow transplant
21. Hospital-acquired candidemia. The attributable mortality and excess length of stay
22. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths
23. Nosocomial candidemia: Risk factors and attributable mortality
24. Microbiological factors influencing the outcome of nosocomial bloodstream infections: A 6-year validated, population-based model
25. Serum levels of ketoconazole in bone marrow transplanted patients
26. Fluconazol prophylaxis of fungal infection in patients with acute leukemia: Results of randomized placebo-controlled, double-blind, multicenter trial
27. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
28. Importance of Candida species other than C. albicans as pathogens in oncology patients
29. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: A review
30. Prospective study of Candida species in patients at a comprehensive cancer center
31. Importance of Candida species other than C. albicans as pathogens in oncology patients
32. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches
33. Impact of Candida species colonization on mortality in patients with cancer
34. Emergence of Candida parapsilosis fungemia as the dominant non-albicans Candida species bloodstream infection at a cancer center in New York
35. Breakthrough Candida tropicalis fungemia during ketoconazole prophylaxis in cancer patients
36. Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: Clinical aspects, predisposing factors, and differential pathogenicity of the causitive strains
37. Candida parapsiolosis fungemia in bone marrow transplantation recipients: Implications for azole prophylactic therapy
38. Candida krusei fungemia: Report of four cases and review of the literature